PMID- 25382325
OWN - NLM
STAT- MEDLINE
DCOM- 20170210
LR  - 20171116
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Linking)
VI  - 127
IP  - 21
DP  - 2014
TI  - Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for 
      induction treatment of active lupus nephritis.
PG  - 3718-23
AB  - BACKGROUND: Lupus nephritis (LN) is one of the most serious manifestations of 
      systemic lupus erythematosus. Although there have been substantial improvements 
      in LN treatment over the last decade, the outcome remains unoptimistic in a 
      considerable percentage of patients. The aim of this study was to evaluate the 
      efficacy and safety of mizoribine (MZR), a novel selective inhibitor of inosine 
      monophosphate dehydrogenase, as induction treatment for active LN in comparison 
      with mycophenolate mofetil (MMF) and intravenous cyclophosphamide (CYC). METHODS: 
      Ninety patients with active LN were observed. Thirty patients were given MZR 
      orally at the dose of 300 mg every other day. Thirty patients took MMF at 2 g per 
      day in two divided doses. Thirty patients received CYC intravenously 0.5 g every 
      2 weeks. Therapeutic effects and adverse events (AEs) were evaluated at the end 
      of 24-week treatment. One-way analysis of variance (ANOVA) followed by Dunn's 
      test was applied to compare the difference among the groups. For comparing 
      categorical data between two groups, chi(2) test was employed. RESULTS: Early 
      responses at week 12 were achieved by 73.3%, 90.0%, and 96.7% in MZR, MMF, and 
      CYC groups, respectively. There was no significant difference in the complete 
      remission rates (22.7%, 24.0%, and 25.0%, respectively) or overall response rates 
      (68.2%, 72.0%, and 75.0%, respectively) among the three groups at week 24. The 
      most prominent drop-down of Systemic Lupus Erythematosus Disease Activity Index 
      scores was observed in MMF or CYC group, and the decline of health assessment 
      questionnaire scores in MZR or MMF group was more prominent than that in the CYC 
      group at week 12. Serum complement 3 (C3) or C4 levels were elevated in all 
      groups after the treatments. CYC was more effective in inhibiting 
      anti-double-stranded DNA antibody, while MZR was more effective in inhibiting 
      antinuclear antibody. The incidences of AEs in patients treated with CYC were 
      significantly higher than those in patients treated with MZR or MMF (24.2% for 
      CYC vs. 3.3% for MZR, and 2.6% for MMF, P = 0.01). CONCLUSIONS: MZR is well 
      tolerated and has an effect similar to MMF in the induction therapy of active LN. 
      MZR may serve as an alternative approach for LN patients.
FAU - Feng, Xuebing
AU  - Feng X
AD  - Department of Rheumatology and Immunology, Affiliated Drum Tower Hospital of 
      Nanjing University Medical School, Nanjing, Jiangsu 210008, China.
FAU - Gu, Fei
AU  - Gu F
AD  - Department of Rheumatology and Immunology, Affiliated Drum Tower Hospital of 
      Nanjing University Medical School, Nanjing, Jiangsu 210008, China.
FAU - Chen, Weiwei
AU  - Chen W
AD  - Department of Rheumatology and Immunology, Affiliated Drum Tower Hospital of 
      Nanjing University Medical School, Nanjing, Jiangsu 210008, China.
FAU - Liu, Yan
AU  - Liu Y
AD  - Department of Rheumatology, Huai'an First People's Hospital, Nanjing Medical 
      University, Huai'an, Jiangsu 223300, China.
FAU - Wei, Hua
AU  - Wei H
AD  - Department of Rheumatology and Immunology, Northern Jiangsu People's Hospital, 
      Yangzhou, Jiangsu 225001, China.
FAU - Liu, Lin
AU  - Liu L
AD  - Department of Rheumatology and Immunology, Central Hospital of Xuzhou City, 
      Xuzhou, Jiangsu 221009, China.
FAU - Yin, Songlou
AU  - Yin S
AD  - Department of Rheumatology and Immunology, Affiliated Hospital of Xuzhou Medical 
      College, Xuzhou, Jiangsu 221002, China.
FAU - Da, Zhanyun
AU  - Da Z
AD  - Department of Rheumatology and Immunology, Affiliated Hospital of Nantong 
      University, Nantong, Jiangsu 226001, China.
FAU - Sun, Lingyun
AU  - Sun L
AD  - Department of Rheumatology and Immunology, Affiliated Drum Tower Hospital of 
      Nanjing University Medical School, Nanjing, Jiangsu 210008, China. Email: 
      lingyunsun2012@163.com.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Ribonucleosides)
RN  - 4JR41A10VP (mizoribine)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - HU9DX48N0T (Mycophenolic Acid)
SB  - IM
MH  - Administration, Intravenous
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Cyclophosphamide/administration & dosage/*therapeutic use
MH  - Enzyme Inhibitors/administration & dosage/*therapeutic use
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/administration & dosage/therapeutic use
MH  - Lupus Nephritis/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Mycophenolic Acid/administration & dosage/*therapeutic use
MH  - Ribonucleosides/administration & dosage/*therapeutic use
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2014/11/11 06:00
MHDA- 2017/02/12 06:00
CRDT- 2014/11/11 06:00
PHST- 2014/11/11 06:00 [entrez]
PHST- 2014/11/11 06:00 [pubmed]
PHST- 2017/02/12 06:00 [medline]
PST - ppublish
SO  - Chin Med J (Engl). 2014;127(21):3718-23.